Increased Serum Concentrations of High Mobility Group Box 1 (HMGB1) Protein in Children with Autism Spectrum Disorder

Overview

Journal Children (Basel)

Specialty Health Services

Date 2021 Jul 2

PMID 34198762

Citations 7

Authors

Gerasimos Makris

Giorgos Chouliaras

Filia Apostolakou

Charalabos Papageorgiou

George P Chrousos

Ioannis Papassotiriou

Panagiota Pervanidou

Affiliations

Soon will be listed here.

Abstract

High mobility group box 1 protein (HMGB1) has been suggested to be involved in the immune dysfunction and inflammation reported in autism spectrum disorder (ASD). We aimed to assess HMGB1 serum concentrations (SCs) in high-functioning ASD children compared to typically developing (TD) controls and to explore their associations with the autism spectrum quotient (AQ), the empathy quotient (EQ), and the systemizing quotient (SQ). The study involved 42 ASD children and 38 TD children, all-male, aged between 6.1 and 13.3 years old. HMGB1 SCs were measured by enzyme-linked immunosorbent assay (ELISA). Groups were comparable regarding age, general IQ, birth weight, and maternal age at birth. ASD children showed significantly higher HMGB1 SCs compared to TD children (1.25 ± 0.84 ng/mL versus 1.13 ± 0.79 ng/mL, respectively, = 0.039). The Spearman's rho revealed that HMGB1 SCs were positively correlated with the AQ attention to detail subscale (rs = 0.46, = 0.045) and with the SQ total score (rs = 0.42, = 0.04) in the ASD group. These results show that HMGB1 serum concentrations are altered in ASD children, and suggest that inflammatory processes mediated by HMGB1 may be associated with specific cognitive features observed in ASD.

Citing Articles

The Interplay of Astrocytes and Neurons in Autism Spectrum Disorder.

Cano A, Santos D, Beltrao-Braga P Adv Neurobiol. 2024; 39:269-284.

PMID: 39190079 DOI: 10.1007/978-3-031-64839-7_11.

Serum HMGB1 and Beclin 1 Levels in Patients with a Diagnosis of Schizophrenia.

Yildiz S, Kazgan Kilicaslan A, Emir B, Ugur K, Kilic F Turk Psikiyatri Derg. 2024; 35(1):1-7.

PMID: 38556931 PMC: 11003366. DOI: 10.5080/u27030.

The Relationship Between Social Skills and Sensory Profile, Emotion Regulation, and Empathizing/Systemizing in Adolescents on the Autism Spectrum.

Kose S, Turer F, Inal Kaleli I, Calik Senturk H, Ozuysal Uyar D, Bildik T J Autism Dev Disord. 2023; 55(1):59-75.

PMID: 38127185 DOI: 10.1007/s10803-023-06190-5.

High Mobility Group Box 1 Protein: A Plausible Therapeutic Molecular Target in Parkinson's Disease.

Goyal A, Agrawal A, Dubey N, Verma A Curr Pharm Biotechnol. 2023; 25(8):937-943.

PMID: 37670710 DOI: 10.2174/1389201025666230905092218.

Advanced Biomarkers of Hepatotoxicity in Psychiatry: A Narrative Review and Recommendations for New Psychoactive Substances.

Golub A, Ordak M, Nasierowski T, Bujalska-Zadrozny M Int J Mol Sci. 2023; 24(11).

PMID: 37298365 PMC: 10253383. DOI: 10.3390/ijms24119413.

References

Yang H, Wang H, Andersson U . Targeting Inflammation Driven by HMGB1. Front Immunol. 2020; 11:484. PMC: 7099994. DOI: 10.3389/fimmu.2020.00484. View

Van der Burg E, Alais D, Cass J . Audiovisual temporal recalibration occurs independently at two different time scales. Sci Rep. 2015; 5:14526. PMC: 4600976. DOI: 10.1038/srep14526. View

Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J . Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2010; 25(1):40-5. PMC: 2991432. DOI: 10.1016/j.bbi.2010.08.003. View

Masi A, Quintana D, Glozier N, Lloyd A, Hickie I, Guastella A . Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2014; 20(4):440-6. DOI: 10.1038/mp.2014.59. View

Zhong H, Li X, Zhou S, Jiang P, Liu X, Ouyang M . Interplay between RAGE and TLR4 Regulates HMGB1-Induced Inflammation by Promoting Cell Surface Expression of RAGE and TLR4. J Immunol. 2020; 205(3):767-775. DOI: 10.4049/jimmunol.1900860. View

Higashida H, Hashii M, Tanaka Y, Matsukawa S, Higuchi Y, Gabata R . CD38, CD157, and RAGE as Molecular Determinants for Social Behavior. Cells. 2019; 9(1). PMC: 7016687. DOI: 10.3390/cells9010062. View

Vezzani A, Maroso M, Balosso S, Sanchez M, Bartfai T . IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun. 2011; 25(7):1281-9. DOI: 10.1016/j.bbi.2011.03.018. View

Tang Y, Zhao X, Antoine D, Xiao X, Wang H, Andersson U . Regulation of Posttranslational Modifications of HMGB1 During Immune Responses. Antioxid Redox Signal. 2015; 24(12):620-34. PMC: 5349223. DOI: 10.1089/ars.2015.6409. View

Enstrom A, Krakowiak P, Onore C, Pessah I, Hertz-Picciotto I, Hansen R . Increased IgG4 levels in children with autism disorder. Brain Behav Immun. 2009; 23(3):389-95. PMC: 2696343. DOI: 10.1016/j.bbi.2008.12.005. View

10.

van der Zee E, Derksen J . The Power of Systemizing in Autism. Child Psychiatry Hum Dev. 2020; 52(2):321-331. DOI: 10.1007/s10578-020-01014-4. View

11.

Stevenson R, Toulmin J, Youm A, Besney R, Schulz S, Barense M . Increases in the autistic trait of attention to detail are associated with decreased multisensory temporal adaptation. Sci Rep. 2017; 7(1):14354. PMC: 5662613. DOI: 10.1038/s41598-017-14632-1. View

12.

Boso M, Emanuele E, Minoretti P, Arra M, Politi P, Ucelli di Nemi S . Alterations of circulating endogenous secretory RAGE and S100A9 levels indicating dysfunction of the AGE-RAGE axis in autism. Neurosci Lett. 2006; 410(3):169-73. DOI: 10.1016/j.neulet.2006.08.092. View

13.

Nadeem A, Ahmad S, Bakheet S, Al-Harbi N, Al-Ayadhi L, Attia S . Toll-like receptor 4 signaling is associated with upregulated NADPH oxidase expression in peripheral T cells of children with autism. Brain Behav Immun. 2016; 61:146-154. DOI: 10.1016/j.bbi.2016.12.024. View

14.

Russo A . Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism Spectrum Disorders (ASDs). J Cent Nerv Syst Dis. 2014; 6:79-83. PMC: 4167315. DOI: 10.4137/JCNSD.S13767. View

15.

Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen R, Croen L . Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol. 2008; 204(1-2):149-53. PMC: 2615583. DOI: 10.1016/j.jneuroim.2008.07.006. View

16.

Fukami A, Adachi H, Yamagishi S, Matsui T, Ueda S, Nakamura K . Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism. 2009; 58(12):1688-93. DOI: 10.1016/j.metabol.2009.05.024. View

17.

Xue J, Suarez J, Minaai M, Li S, Gaudino G, Pass H . HMGB1 as a therapeutic target in disease. J Cell Physiol. 2020; 236(5):3406-3419. PMC: 8104204. DOI: 10.1002/jcp.30125. View

18.

Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H . Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflammation. 2008; 5:52. PMC: 2625336. DOI: 10.1186/1742-2094-5-52. View

19.

Chan J, Roth J, Oppenheim J, Tracey K, Vogl T, Feldmann M . Alarmins: awaiting a clinical response. J Clin Invest. 2012; 122(8):2711-9. PMC: 3408740. DOI: 10.1172/JCI62423. View

20.

Onore C, Careaga M, Ashwood P . The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun. 2011; 26(3):383-92. PMC: 3418145. DOI: 10.1016/j.bbi.2011.08.007. View